Optimization and Assessment of Quantitative 124I Imaging on a Philips Gemini Dual GS PET/CT System

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2009 Mar 17

PMID 19288099

Citations 10

Authors

Rebecca A Gregory

Claire A Hooker

Mike Partridge

Glenn D Flux

Affiliations

Soon will be listed here.

Abstract

Purpose: Quantitative (124)I PET imaging is challenging as (124)I has a complex decay scheme. In this study the performance of a Philips Gemini dual GS PET/CT system was optimized and assessed for (124)I.

Methods: The energy window giving the maximum noise equivalent count rate (NECR) and NEMA 2001-NU2 image quality were measured. The activity concentration (AC) accuracy of images calibrated using factors from (18)F and (124)I decaying source measurements were investigated.

Results: The energy window 455-588 keV gave the maximum NECR of 9.67 kcps for 233 MBq. (124)I and (18)F image quality was comparable, although (124)I background variability was increased. The average underestimation in AC in (124)I images was 17.9 +/- 2.9% for nonuniform background and 14.7 +/- 2.9% for single scatter simulation (SSS) subtraction scatter correction. At 224 MBq the underestimation was 10.8 +/- 11.3%, which is comparable to 7.7 +/- 5.3% for (18)F, but increased with decreasing activity.

Conclusions: The best (124)I PET quantitative accuracy was achieved for the optimized energy window, using SSS scatter correction and calibration factors from decaying (124)I source measurements. The quantitative accuracy for (124)I was comparable to that for (18)F at high activities of 224 MBq but diminishing with decreasing activity. Specific corrections for prompt gamma-photons may further improve the quantitative accuracy.

Citing Articles

EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for I mIBG treatment of neuroendocrine tumours.

Gear J, Chiesa C, Lassmann M, Minguez Gabina P, Tran-Gia J, Stokke C EJNMMI Phys. 2020; 7(1):15.

PMID: 32144574 PMC: 7060302. DOI: 10.1186/s40658-020-0282-7.

Improved Quantification of F-FDG PET during I-Rituximab Therapy on Mouse Lymphoma Models after I Prompt Emission Correction.

Lee Y, Kim H, Kim J Diagnostics (Basel). 2019; 9(4).

PMID: 31597334 PMC: 6963650. DOI: 10.3390/diagnostics9040144.

Physics of pure and non-pure positron emitters for PET: a review and a discussion.

Conti M, Eriksson L EJNMMI Phys. 2016; 3(1):8.

PMID: 27271304 PMC: 4894854. DOI: 10.1186/s40658-016-0144-5.

Comparison of Imaging Characteristics of (124)I PET for Determination of Optimal Energy Window on the Siemens Inveon PET.

Yu A, Kim H, Lim S, Kim J Biomed Res Int. 2016; 2016:3067123.

PMID: 27127782 PMC: 4820595. DOI: 10.1155/2016/3067123.

Is the image quality of I-124-PET impaired by an automatic correction of prompt gammas?.

Preylowski V, Schlogl S, Schoenahl F, Jorg G, Samnick S, Buck A PLoS One. 2013; 8(8):e71729.

PMID: 24014105 PMC: 3754939. DOI: 10.1371/journal.pone.0071729.

References

Langen K, Coenen H, Roosen N, Kling P, Muzik O, Herzog H . SPECT studies of brain tumors with L-3-[123I] iodo-alpha-methyl tyrosine: comparison with PET, 124IMT and first clinical results. J Nucl Med. 1990; 31(3):281-6. View

Westera G, Reist H, Buchegger F, Heusser C, Hardman N, Pfeiffer A . Radioimmuno positron emission tomography with monoclonal antibodies: a new approach to quantifying in vivo tumour concentration and biodistribution for radioimmunotherapy. Nucl Med Commun. 1991; 12(5):429-37. View

Dekker B, Keen H, Lyons S, Disley L, Hastings D, Reader A . MBP-annexin V radiolabeled directly with iodine-124 can be used to image apoptosis in vivo using PET. Nucl Med Biol. 2005; 32(3):241-52. DOI: 10.1016/j.nucmedbio.2004.11.006. View

Jentzen W, Weise R, Kupferschlager J, Freudenberg L, Brandau W, Bares R . Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging. 2007; 35(3):611-23. DOI: 10.1007/s00259-007-0554-7. View

Flower M, Schlesinger T, Hinton P, Adam I, Masoomi A, Elbelli M . Radiation dose assessment in radioiodine therapy. 2. Practical implementation using quantitative scanning and PET, with initial results on thyroid carcinoma. Radiother Oncol. 1989; 15(4):345-57. DOI: 10.1016/0167-8140(89)90081-9. View

Iozzo P, Osman S, Glaser M, Knickmeier M, Ferrannini E, Pike V . In vivo imaging of insulin receptors by PET: preclinical evaluation of iodine-125 and iodine-124 labelled human insulin. Nucl Med Biol. 2002; 29(1):73-82. DOI: 10.1016/s0969-8051(01)00286-4. View

Erdi Y, Macapinlac H, Larson S, Erdi A, Yeung H, Furhang E . Radiation Dose Assessment for I-131 Therapy of Thyroid Cancer Using I-124 PET Imaging. Clin Positron Imaging. 2003; 2(1):41-46. DOI: 10.1016/s1095-0397(99)00004-7. View

Sgouros G, Kolbert K, Sheikh A, Pentlow K, Mun E, Barth A . Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med. 2004; 45(8):1366-72. View

Daghighian F, Pentlow K, Larson S, Graham M, DiResta G, Yeh S . Development of a method to measure kinetics of radiolabelled monoclonal antibody in human tumour with applications to microdosimetry: positron emission tomography studies of iodine-124 labelled 3F8 monoclonal antibody in glioma. Eur J Nucl Med. 1993; 20(5):402-9. DOI: 10.1007/BF00208998. View

10.

Freudenberg L, Jentzen W, Gorges R, Petrich T, Marlowe R, Knust J . 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin. 2007; 46(4):121-8. View

11.

Accorsi R, Adam L, Werner M, Karp J . Optimization of a fully 3D single scatter simulation algorithm for 3D PET. Phys Med Biol. 2004; 49(12):2577-98. DOI: 10.1088/0031-9155/49/12/008. View

12.

Wilson C, Snook D, Dhokia B, Taylor C, Watson I, Lammertsma A . Quantitative measurement of monoclonal antibody distribution and blood flow using positron emission tomography and 124iodine in patients with breast cancer. Int J Cancer. 1991; 47(3):344-7. DOI: 10.1002/ijc.2910470305. View

13.

Shaul M, Abourbeh G, Jacobson O, Rozen Y, Laky D, Levitzki A . Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer. Bioorg Med Chem. 2004; 12(13):3421-9. DOI: 10.1016/j.bmc.2004.04.044. View

14.

Larson S, Pentlow K, Volkow N, Wolf A, Finn R, Lambrecht R . PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J Nucl Med. 1992; 33(11):2020-3. View

15.

Collingridge D, Carroll V, Glaser M, Aboagye E, Osman S, Hutchinson O . The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res. 2002; 62(20):5912-9. View

16.

Guzzardi R, Bellina C, Knoop B, Jordan K, Ostertag H, Reist H . Methodologies for performance evaluation of positron emission tomographs. J Nucl Biol Med (1991). 1991; 35(3):141-57. View

17.

Blasberg R, Roelcke U, Weinreich R, Beattie B, von Ammon K, Yonekawa Y . Imaging brain tumor proliferative activity with [124I]iododeoxyuridine. Cancer Res. 2000; 60(3):624-35. View

18.

Karp J, Muehllehner G, Mankoff D, Ordonez C, Ollinger J, Daube-Witherspoon M . Continuous-slice PENN-PET: a positron tomograph with volume imaging capability. J Nucl Med. 1990; 31(5):617-27. View

19.

Ott R, Tait D, Flower M, Babich J, Lambrecht R . Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography. Br J Radiol. 1992; 65(777):787-91. DOI: 10.1259/0007-1285-65-777-787. View

20.

Roelcke U, Hausmann O, Merlo A, Missimer J, Maguire R, Freitag P . PET imaging drug distribution after intratumoral injection: the case for (124)I-iododeoxyuridine in malignant gliomas. J Nucl Med. 2002; 43(11):1444-51. View